Late treatment study
et al., ChiCTR2000029741 (Preprint)
Efficacy of Ch loroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study
Early results from a very small trial, reported within the application for a later trial. Very minimal details are provided, but we include this as the earliest published results. For COVID-19 patients with pneumonia the viral negative conversion rate was 50% (5/10) with C
Q versus 20% (3/15) with lopinavir/ritonavir.
no virological cure, ↓37.5%, p=0.17
Please send us corrections, updates, or comments.